AFT Pharmaceuticals 관리

관리 기준 확인 3/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Hartley Atkinson

최고 경영자

NZ$974.8k

총 보상

CEO 급여 비율	68.7%
CEO 임기	27.2yrs
CEO 소유권	68.7%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	6.7yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Hartley Atkinson 의 보수는 AFT Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	NZ$12m
Jun 30 2024	n/a	n/a	NZ$14m
Mar 31 2024	NZ$975k	NZ$670k	NZ$16m
Dec 31 2023	n/a	n/a	NZ$13m
Sep 30 2023	n/a	n/a	NZ$11m
Jun 30 2023	n/a	n/a	NZ$11m
Mar 31 2023	NZ$931k	NZ$606k	NZ$11m
Dec 31 2022	n/a	n/a	NZ$14m
Sep 30 2022	n/a	n/a	NZ$17m
Jun 30 2022	n/a	n/a	NZ$18m
Mar 31 2022	NZ$840k	NZ$578k	NZ$20m
Dec 31 2021	n/a	n/a	NZ$15m
Sep 30 2021	n/a	n/a	NZ$11m
Jun 30 2021	n/a	n/a	NZ$9m
Mar 31 2021	NZ$701k	NZ$506k	NZ$8m
Dec 31 2020	n/a	n/a	NZ$5m
Sep 30 2020	n/a	n/a	NZ$3m
Jun 30 2020	n/a	n/a	NZ$7m
Mar 31 2020	NZ$592k	NZ$443k	NZ$12m
Dec 31 2019	n/a	n/a	NZ$11m
Sep 30 2019	n/a	n/a	NZ$11m
Jun 30 2019	n/a	n/a	NZ$4m
Mar 31 2019	NZ$556k	NZ$431k	-NZ$3m
Dec 31 2018	n/a	n/a	-NZ$7m
Sep 30 2018	n/a	n/a	-NZ$11m
Jun 30 2018	n/a	n/a	-NZ$12m
Mar 31 2018	NZ$514k	NZ$429k	-NZ$14m

보상 대 시장: Hartley 의 총 보상 ($USD 568.29K )은 Australian 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 706.54K ).

보상과 수익: Hartley 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Hartley Atkinson

27.2yrs

테뉴어

NZ$974,785

보상

Dr. Hartley Atkinson, M.Pharm (Dist), PhD, is Co-Founder of AFT Pharmaceuticals Limited in 1997. Dr. Atkinson is Chief Executive Officer of AFT Pharmaceuticals Limited since September 04, 1997 and also ser...

이사회 구성원

이름	위치	테뉴어	보상	소유권
Hartley Atkinson	Co-Founder	27.2yrs	NZ$974.79k	68.69% A$ 175.1m
Marree Atkinson	Co-Founder	12.2yrs	NZ$175.44k	데이터 없음
Theodore Witek	Independent Non-Executive Director	3.9yrs	NZ$161.04k	데이터 없음
David Flacks	Independent Chairman	9.4yrs	NZ$154.00k	0.17% A$ 434.6k
Andrew Lane	Independent Non-Executive Director	1.2yrs	NZ$50.38k	데이터 없음
Allison Yorston	Independent Non-Executive Director	no data	데이터 없음	데이터 없음

6.7yrs

평균 재임 기간

경험이 풍부한 이사회: AFP 의 이사회는 경험(평균 재직 기간 6.7 년)으로 간주됩니다.

AFT Pharmaceuticals 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

AFT Pharmaceuticals Limited, Annual General Meeting, Aug 02, 2024

AFT Pharmaceuticals Announces Board Changes

AFT Pharmaceuticals Limited, Annual General Meeting, Aug 04, 2023

Dr. Doug Wilson to Step Down from AFT Pharmaceuticals Board

AFT Pharmaceuticals Limited, Annual General Meeting, Aug 05, 2022

Independent Director recently bought AU$62k worth of stock

Recent updates

First half 2025 earnings released: NZ$0.02 loss per share (vs NZ$0.02 profit in 1H 2024)

Investor sentiment deteriorates as stock falls 16%

AFT Pharmaceuticals Limited to Report First Half, 2025 Results on Nov 21, 2024

Upcoming dividend of NZ$0.016 per share

New minor risk - Share price stability

AFT Pharmaceuticals Limited, Annual General Meeting, Aug 02, 2024

Dividend of NZ$0.016 announced

Full year 2024 earnings released: EPS: NZ$0.15 (vs NZ$0.10 in FY 2023)

AFT Pharmaceuticals Limited to Report Fiscal Year 2024 Results on May 23, 2024

Investor sentiment deteriorates as stock falls 17%

Now 21% undervalued

AFT Pharmaceuticals Limited Reaffirms Earnings Guidance for the Fiscal Year 2024

Now 20% undervalued after recent price drop

AFT Pharmaceuticals Limited to Report First Half, 2024 Results on Nov 23, 2023

AFT Pharmaceuticals Announces Board Changes

Now 20% undervalued

AFT Pharmaceuticals Limited, Annual General Meeting, Aug 04, 2023

Investor sentiment improves as stock rises 20%

AFT Pharmaceuticals Limited Provides Earnings Guidance for the Year Ending March 2024

AFT Pharmaceuticals Limited to Report Fiscal Year 2023 Results on May 22, 2023

First half 2023 earnings released: EPS: NZ$0.01 (vs NZ$0.04 in 1H 2022)

AFT Pharmaceuticals Limited to Report First Half, 2023 Results on Nov 24, 2022

AFT Pharmaceuticals Limited Update on Maxigesic IV Us Registration Filing

AFT Pharmaceuticals Limited Completes Pascomer Clinical Study

Dr. Doug Wilson to Step Down from AFT Pharmaceuticals Board

US FDA Seeks More Information on AFT Pharmaceuticals Limited's Maxigesic IV Application

Investor sentiment improved over the past week

AFT Pharmaceuticals Limited, Annual General Meeting, Aug 05, 2022

Full year 2022 earnings released: EPS: NZ$0.19 (vs NZ$0.074 in FY 2021)

Full year 2022 earnings released: EPS: NZ$0.19 (vs NZ$0.074 in FY 2021)

AFT Pharmaceuticals Limited Provides Earnings Guidance for the Year to 31 March 2023

AFT Pharmaceuticals Limited to Report Fiscal Year 2022 Results on May 23, 2022

AFT Pharmaceuticals Announces US Food and Drug Administration Approve Topical Treatment Indicated for Facial Angiofibroma

Independent Director recently bought AU$62k worth of stock

Independent Director recently bought AU$161k worth of stock

AFT Pharmaceuticals Limited Welcomes Australian Federal Court Appeal Success

First half 2022 earnings released: EPS NZ$0.04 (vs NZ$0.01 in 1H 2021)

AFT Pharmaceuticals Got First Regulatory Approval of Maxigesic Oral Liquid in Europe

Full year 2021 earnings released

AFT Pharmaceuticals Limited Announces Earnings Guidance for the Fiscal Year 2022

AFT Pharmaceuticals Revises Earnings Guidance for the Year to 31 March 2021

AFT Pharmaceuticals Signs an Exclusive Maxigesic IV Licensing Agreement for Eight New European Markets

New 90-day low: AU$4.00

New 90-day high: AU$5.11

New 90-day low: AU$4.10

AFT Pharmaceuticals Limited Appoints Anita Baldauf as Non-Executive Director

Revenue misses expectations

AFT Pharmaceuticals Limited Appoints Eddie Townslie as the Local Director of AFT Pharmaceuticals Europe

New 90-day high: AU$5.00

AFT Pharmaceuticals Receives a US Food and Drug Administration Complete Response Letter Covering Its Application for the Approval of A Tablet Version of Its Maxigesic® Pain Relief Medication

AFT Pharmaceuticals Limited and Setek Sign Supply Agreement

AFT Pharmaceuticals Limited Appoints Anita Baldauf as a Non-Executive Director

AFT Pharmaceuticals Limited to Report First Half, 2021 Results on Nov 19, 2020

New 90-day high - AU$4.65

CEO 보상 분석

CEO

테뉴어

보상

이사회 구성원

평균 재임 기간